Differential spatial approximation between secretin and its receptor residues in active and inactive conformations demonstrated by photoaffinity labeling.

Understanding of the conformational changes in G protein-coupled receptors associated with activation and inactivation is of great interest. We previously used photoaffinity labeling to elucidate spatial approximations between photolabile residues situated throughout the pharmacophore of secretin agonist probes and this receptor. The aim of the current work was to develop analogous photolabile secretin antagonist probes and to explore their spatial approximations. The most potent secretin antagonist reported is a pseudopeptide ([psi(4, 5)]secretin) in which the peptide bond between residues 4 and 5 was replaced by a psi(CH(2)-NH) peptide bond isostere. We have developed a series of [psi(4, 5)]secretin analogs incorporating photolabile benzoyl phenylalanine residues in positions 6, 22, and 26. Each bound to the secretin receptor saturably and specifically, with affinity similar to their parental peptide. At concentrations with no measurable agonist activity, each probe covalently labeled the secretin receptor. Peptide mapping using proteolytic cleavage, immunoprecipitation, and radiochemical sequencing identified that each of these three probes labeled the amino terminus of the secretin receptor. Whereas the position 22 probe labeled the same residue as its analogous agonist probe and the position 6 probe labeled a residue within two residues of that labeled by its analogous agonist probe, the position 26 probe labeled a site 16 residues away from that labeled by its analogous agonist probe. Thus, whereas structurally related agonist and antagonist probes dock in the same general region of this receptor, conformational differences in active and inactive states result in substantial differences in spatial approximation at the carboxyl-terminal end of secretin analogs.

[1]  L. Miller,et al.  Paired Cysteine Mutagenesis to Establish the Pattern of Disulfide Bonds in the Functional Intact Secretin Receptor* , 2005, Journal of Biological Chemistry.

[2]  R. Riek,et al.  NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Miller,et al.  Molecular Approximation between a Residue in the Amino-terminal Region of Calcitonin and the Third Extracellular Loop of the Class B G Protein-coupled Calcitonin Receptor* , 2004, Journal of Biological Chemistry.

[4]  T. Lybrand,et al.  Spatial Approximation between the Amino Terminus of a Peptide Agonist and the Top of the Sixth Transmembrane Segment of the Secretin Receptor* , 2004, Journal of Biological Chemistry.

[5]  T. Lybrand,et al.  Spatial Approximation between Two Residues in the Mid-region of Secretin and the Amino Terminus of Its Receptor , 2003, Journal of Biological Chemistry.

[6]  W. Fischer,et al.  A Soluble Form of the First Extracellular Domain of Mouse Type 2β Corticotropin-releasing Factor Receptor Reveals Differential Ligand Specificity* , 2003, The Journal of Biological Chemistry.

[7]  T. Lybrand,et al.  Spatial approximation between a photolabile residue in position 13 of secretin and the amino terminus of the secretin receptor. , 2003, Molecular pharmacology.

[8]  T. Lybrand,et al.  Interaction among four residues distributed through the secretin pharmacophore and a focused region of the secretin receptor amino terminus. , 2002, Molecular endocrinology.

[9]  R. B. Merrifield,et al.  Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling. , 2002, Biochemistry.

[10]  R. Rudolph,et al.  In vitro folding, functional characterization, and disulfide pattern of the extracellular domain of human GLP-1 receptor. , 2002, Biophysical chemistry.

[11]  L. Miller,et al.  Molecular pharmacology of the secretin receptor. , 2002, Receptors & channels.

[12]  P. Sexton,et al.  Molecular pharmacology of the calcitonin receptor. , 2002, Receptors & channels.

[13]  M. Chorev.  Parathyroid hormone 1 receptor: insights into structure and function. , 2002, Receptors & channels.

[14]  A. Couvineau,et al.  VPAC receptors for VIP and PACAP. , 2002, Receptors & channels.

[15]  W. Fischer,et al.  Expression, Purification, and Characterization of a Soluble Form of the First Extracellular Domain of the Human Type 1 Corticotropin Releasing Factor Receptor* , 2001, The Journal of Biological Chemistry.

[16]  Y. Asmann,et al.  Identification of Two Pairs of Spatially Approximated Residues within the Carboxyl Terminus of Secretin and Its Receptor* , 2000, The Journal of Biological Chemistry.

[17]  R. Rudolph,et al.  The N-terminal fragment of human parathyroid hormone receptor 1 constitutes a hormone binding domain and reveals a distinct disulfide pattern. , 2000, Biochemistry.

[18]  G. Bitan,et al.  Photoaffinity Cross-linking Identifies Differences in the Interactions of an Agonist and an Antagonist with the Parathyroid Hormone/Parathyroid Hormone-related Protein Receptor* , 2000, The Journal of Biological Chemistry.

[19]  L. Miller,et al.  Identification of an Interaction between Residue 6 of the Natural Peptide Ligand and a Distinct Residue within the Amino-terminal Tail of the Secretin Receptor* , 1999, The Journal of Biological Chemistry.

[20]  L. Miller,et al.  Demonstration of a Direct Interaction between Residue 22 in the Carboxyl-terminal Half of Secretin and the Amino-terminal Tail of the Secretin Receptor Using Photoaffinity Labeling* , 1999, The Journal of Biological Chemistry.

[21]  L. Suva,et al.  Parathyroid Hormone-Receptor Interactions Identified Directly by Photocross-linking and Molecular Modeling Studies* , 1998, The Journal of Biological Chemistry.

[22]  L. Miller,et al.  Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis. , 1998, The Journal of pharmacology and experimental therapeutics.

[23]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[24]  T. Lybrand,et al.  Direct Identification of a Second Distinct Site of Contact between Cholecystokinin and Its Receptor* , 1998, The Journal of Biological Chemistry.

[25]  L. Miller,et al.  Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. , 1998, Gastroenterology.

[26]  B. Wulff,et al.  The C‐terminal part of VIP is important for receptor binding and activation, as evidenced by chimeric constructs of VIP/secretin , 1997, FEBS letters.

[27]  P. Sexton,et al.  Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system. , 1997, Molecular pharmacology.

[28]  L. Miller,et al.  Relationship Between Native and Recombinant Cholecystokinin Receptors: Role of Differential Glycosylation , 1996, Pancreas.

[29]  U. Lessel,et al.  NMR spectroscopic evidence that helodermin, unlike other members of the secretin/VIP family of peptides, is substantially structured in water. , 1996, Biochemistry.

[30]  V. Hruby,et al.  Synthesis using a Fmoc-based strategy and biological activities of some reduced peptide bond pseudopeptide analogues of dynorphin A1. , 1995, Journal of medicinal chemistry.

[31]  L. Miller,et al.  Critical Contributions of Amino-terminal Extracellular Domains in Agonist Binding and Activation of Secretin and Vasoactive Intestinal Polypeptide Receptors. STUDIES OF CHIMERIC RECEPTORS (*) , 1995, The Journal of Biological Chemistry.

[32]  S. Goldring,et al.  Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family , 1993, Trends in Endocrinology & Metabolism.

[33]  L. Miller,et al.  Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors. , 1993, Gastroenterology.

[34]  H. Kofod.  Synthesis of biologically active porcine secretin and [ITyr10] porcine secretin. , 2009, International journal of peptide and protein research.

[35]  R. Jensen,et al.  Reduced peptide bond pseudopeptide analogues of secretin. A new class of secretin receptor antagonists. , 1991, The Journal of biological chemistry.

[36]  M. Nilges,et al.  Conformation of secretin in dimethyl sulfoxide solution , 1989 .

[37]  L. Miller,et al.  Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides. , 2009, International journal of peptide and protein research.

[38]  A. Gronenborn,et al.  Determination of the backbone conformation of secretin by restrained molecular dynamics on the basis of interproton distance data. , 1988, European journal of biochemistry.

[39]  A. Gronenborn,et al.  A 1H‐NMR study of the solution conformation of secretin resonance assignment and secondary structure , 1987, FEBS letters.

[40]  M. Bodanszky,et al.  Conformation of peptides of the secretin-VIP-glucagon family in solution , 1986, Peptides.

[41]  J. T. Turner,et al.  A fragment of vasoactive intestinal peptide, VIP(10–28), is an antagonist of VIP in the colon carcinoma cell line, HT29 , 1986, Peptides.

[42]  D Rodbard,et al.  Ligand: a versatile computerized approach for characterization of ligand-binding systems. , 1980, Analytical biochemistry.

[43]  J. Gardner,et al.  Interaction of synthetic 10-tyrosyl analogues of secretin with hormone receptors on pancreatic acinar cells. , 1977, Gastroenterology.

[44]  P. Robberecht,et al.  Interaction of porcine vasoactive intestinal peptide with dispersed pancreatic acinar cells from the guinea pig. Structural requirements for effects of vasoactive intestinal peptide and secretin on cellular adenosine 3':5'-monophosphate. , 1976, The Journal of biological chemistry.